Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | IMGN632, a novel CD123-targeting antibody-drug conjugate for untreated and R/R BPDCN

It has been shown that all patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) overexpress CD123. In this video, Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, talks on IMGN632, a novel CD123-targeting antibody-drug conjugate (ADC) in development for the treatment of patients with BPDCN. A Phase I/II clinical trial is currently evaluating this agent in both the frontline and relapsed/refractory (R/R) settings (NCT03386513) and is showing promising safety and efficacy results. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Disclosures

Naveen Pemmaraju, MD, is a member of the ASH Communications Committee and the ASCO Leukemia Advisory panel; has participated in consultancy work for Pacylex Pharmaceuticals, ImmuniGen, Bristol Myers Squibb, Blueprint Medicines, Clearview Healthcare Partners, Astellas Pharma US Inc., Triptych Health Partners and CTI Biopharma; has received grants from Affymetrix and SagerStrong Foundation; has received honoraria from Incyte, Novartis, LFB Biotechnologies, Stemline Therapeutics, Celgene, AbbVie, MustangBio, Roche Diagnostics, Blueprint Medicines, DAVA Oncology, Springer Science + Business Media LLC, Aptitude Health, NeoPharm Israel and CareDx, Inc., has received research support from Novartis, Stemline Therapeutics, Samus Therapeutics, AbbVie, Cellectis, Affymetrix, Daiichi Sankyo and Plexxikon; and has received travel reimbursement from Stemline Therapeutics, Celgene, MustangBio, DAVA Oncology and AbbVie.